CTOs on the Move

Relay Therapeutics

www.relaytx.com

 
Relay Therapeutics is building the world`s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.relaytx.com
  • 215 First Street 3rd Floor
    Cambridge, MA USA 02142
  • Phone: 617.370.8837

Executives

Name Title Contact Details

Funding

Relay Therapeutics raised $57M on 09/15/2016
Relay Therapeutics raised $63M on 12/14/2017
Relay Therapeutics raised $400M on 12/20/2018

Similar Companies

Aqualung Therapeutics

Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension.

BioStar Consulting

BioStar Consulting, Inc. is a Greenbrier, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio-Kinetic Clinical Applications

Bio-Kinetic Clinical Applications is a Springfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xigo Nanotools

Xigo Nanotools is a Morganville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QurAlis

QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.